AIM: To investigate the ornithine decarboxylase (ODC) gene expression in colorectal carcinoma, ODC mRNA was assayed by RT-PCR and ODC protein was detected by a monoclonal antibody against fusion of human colon ODC prepared by hybridoma technology. METHODS: Total RNA was extracted from human colorectal cancer tissues and their normal counterpart tissues. ODC mRNA levels were examined by RT-PCR. ODC genes amplified from RT-PCR were cloned into a prokaryotic vector pQE-30. The expressed proteins were purified by chromatography. Anti-ODC mAb was prepared with classical hybridoma techniques and used to determine the ODC expression in colon cancer tissues by immunohistochemical and Western blotting assay. RESULTS: A cell line, which could steadily secrete anti-ODC mAb, was selected through subcloning four times. Western blotting reconfirmed the mAb and ELISA showed that its subtype was IgG2a. RT-PCR showed that the ODC mRNA level increased greatly in colon cancer tissues (P<0.01). Immunohistochemical staining showed that colorectal carcinoma cells expressed a significantly higher level of ODC than normal colorectal mucosa (98.6+/-1.03% vs 5.26+/-5%, P<0.01). CONCLUSION: ODC gene overexpression is significantly related to human colorectal carcinoma. ODC gene expression may be a marker for the gene diagnosis and therapy of colorectal carcinoma.
AIM: To investigate the ornithine decarboxylase (ODC) gene expression in colorectal carcinoma, ODC mRNA was assayed by RT-PCR and ODC protein was detected by a monoclonal antibody against fusion of human colon ODC prepared by hybridoma technology. METHODS: Total RNA was extracted from humancolorectal cancer tissues and their normal counterpart tissues. ODC mRNA levels were examined by RT-PCR. ODC genes amplified from RT-PCR were cloned into a prokaryotic vector pQE-30. The expressed proteins were purified by chromatography. Anti-ODC mAb was prepared with classical hybridoma techniques and used to determine the ODC expression in colon cancer tissues by immunohistochemical and Western blotting assay. RESULTS: A cell line, which could steadily secrete anti-ODC mAb, was selected through subcloning four times. Western blotting reconfirmed the mAb and ELISA showed that its subtype was IgG2a. RT-PCR showed that the ODC mRNA level increased greatly in colon cancer tissues (P<0.01). Immunohistochemical staining showed that colorectal carcinoma cells expressed a significantly higher level of ODC than normal colorectal mucosa (98.6+/-1.03% vs 5.26+/-5%, P<0.01). CONCLUSION:ODC gene overexpression is significantly related to humancolorectal carcinoma. ODC gene expression may be a marker for the gene diagnosis and therapy of colorectal carcinoma.
Authors: H Pendeville; N Carpino; J C Marine; Y Takahashi; M Muller; J A Martial; J L Cleveland Journal: Mol Cell Biol Date: 2001-10 Impact factor: 4.272
Authors: Michele Linsalata; Maria G Caruso; Silvana Leo; Vito Guerra; Benedetta D'Attoma; Alfredo Di Leo Journal: Anticancer Res Date: 2002 Jul-Aug Impact factor: 2.480
Authors: T A Rich; J M Skibber; J A Ajani; D J Buchholz; K R Cleary; R A Dubrow; B Levin; P M Lynch; S H Meterissian; L D Roubein Journal: Int J Radiat Oncol Biol Phys Date: 1995-07-15 Impact factor: 7.038
Authors: Gaurav Kumar; Jagan Mohan R Patlolla; Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Laura Biddick; Anil Singh; Allison Gillaspy; Stanley Lightfoot; Vernon E Steele; Levy Kopelovich; Chinthalapally V Rao Journal: Am J Cancer Res Date: 2016-05-01 Impact factor: 6.166
Authors: Altaf Mohammed; Naveena B Janakiram; Venkateshwar Madka; Rebekah L Ritchie; Misty Brewer; Laura Biddick; Jagan Mohan R Patlolla; Michael Sadeghi; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao Journal: Cancer Prev Res (Phila) Date: 2014-09-23
Authors: Renee C Geck; Jackson R Foley; Tracy Murray Stewart; John M Asara; Robert A Casero; Alex Toker Journal: J Biol Chem Date: 2020-03-05 Impact factor: 5.157